Shalini Sharp joined our Board of Directors as a member of the Audit Committee in September 2024 and was appointed chair of that committee in March 2025. She was appointed a member of the Nominating and Corporate Governance Committee in January 2025.
Ms. Sharp is a leading financial executive with extensive experience in the pharmaceutical and investment banking industries. Ms. Sharp currently serves as a Board member of Neurocrine Biosciences and Organon & Co. Previously, she served on the Boards of Mirati Therapeutics, Sutro Biopharma, Precision Biosciences, Panacea Acquisition Corp., Array Biopharma and Agenus Inc.
Ms. Sharp previously served as Chief Financial Officer and Executive Vice President at Ultragenyx and Chief Financial Officer and Vice President at Agenus. She previously held positions at Elan Pharmaceuticals, McKinsey & Company and Goldman Sachs.
Ms. Sharp earned a B.A. and an MBA from Harvard University.